Hypoxia modulates the activity of a series of clinically approved tyrosine kinase inhibitors

British Journal of Pharmacology

Volumn 171, Issue 1, 2014, Pages 224-236

  Ahmadi, M ^a   Ahmadihosseini, Z ^a   Allison, S J ^a   Begum, S ^a   Rockley, K ^a   Sadiq, M ^a   Chintamaneni, S ^a   Lokwani, R ^a   Hughes, N ^a   Phillips, R M ^a  

^a UNIVERSITY OF BRADFORD   (United Kingdom)

Author keywords

dasatinib; HIF1; hypoxia; sorafenib; Src; tyrosine kinase inhibitors

Indexed keywords

DASATINIB; DOXORUBICIN; ERLOTINIB; FLUOROURACIL; GEFITINIB; HYPOXIA INDUCIBLE FACTOR 1; IMATINIB; MASITINIB; MITOGEN ACTIVATED PROTEIN KINASE; NILOTINIB; OXYGEN; PROTEIN TYROSINE KINASE; PROTEIN TYROSINE KINASE INHIBITOR; RAF PROTEIN; SORAFENIB; SUNITINIB; TIRAPAZAMINE; TYROSINE; VANDETANIB; VINBLASTINE;

AEROBIC METABOLISM; ARTICLE; CANCER CELL; CANCER RESISTANCE; CELL HYPOXIA; CHEMOSENSITIVITY; CONTROLLED STUDY; DRUG APPROVAL; DRUG CYTOTOXICITY; DRUG DETERMINATION; DRUG EFFECT; DRUG MECHANISM; DRUG TARGETING; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION;

DASATINIB; HIF1; HYPOXIA; SORAFENIB; SRC; TYROSINE KINASE INHIBITORS;

ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL HYPOXIA; CELL SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG RESISTANCE, NEOPLASM; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; HUMANS; INHIBITORY CONCENTRATION 50; MAP KINASE KINASE KINASES; MCF-7 CELLS; MOLECULAR TARGETED THERAPY; NEOPLASMS; OXYGEN; PHOSPHORYLATION; PROTEIN KINASE INHIBITORS; PROTEIN-TYROSINE KINASES; RAF KINASES; RECEPTOR, EPIDERMAL GROWTH FACTOR; SIGNAL TRANSDUCTION; SRC-FAMILY KINASES;

EID: 84890284497     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/bph.12438     Document Type: Article

References (46)

1. Allison SJ, Jiang M, Milner J, (2009). Oncogenic viral protein HPV E7 up-regulates the SIRT1 longevity protein in human cervical cancer cells. Aging 1: 316-327.
2. Brahimi-Horn MC, Ben-Hail D, Ilie M, Gounon P, Rouleau M, Hofman V, et al. (2012). Expression of a truncated active form of VDAC1 in lung cancer associates with hypoxic cell survival and correlates with progression to chemotherapy resistance. Cancer Res 72: 2140-2150.
3. Brown JM, (2002). Tumor microenvironment and the response to anticancer therapy. Cancer Biol Ther 1: 453-458.
4. Challen GA, Little MH, (2006). A side order of stem cells: the SP phenotype. Stem Cells 24: 3-12.
5. Chan DA, Sutphin PD, Denko NC, Giaccia AJ, (2002). Role of prolyl hydroxylation in oncogenically stabilized hypoxia-inducible factor-1alpha. J Biol Chem 277: 40112-40117.
6. Filippi I, Naldini A, Carraro F, (2011). Role of the hypoxic microenvironment in the antitumor activity of tyrosine kinase inhibitors. Curr Med Chem 18: 2885-2892.
7. Flamant L, Roegiers E, Pierre M, Hayez A, Sterpin C, De Backer O, et al. (2012). TMEM45A is essential for hypoxia-induced chemoresistance in breast and liver cancer cells. BMC Cancer 12: 391.
8. Harrison LR, Micha D, Brandenburg M, Simpson KL, Morrow CJ, Denneny O, et al. (2011). Hypoxic human cancer cells are sensitized to BH-3 mimetic-induced apoptosis via downregulation of the Bcl-2 protein Mcl-1. J Clin Invest 121: 1075-1087.
9. Heldin CH, Rubin K, Pietras K, Ostman A, (2004). High interstitial fluid pressure-an obstacle in cancer therapy. Nat Rev Cancer 4: 806-813.
10. Kennedy KA, Rockwell S, Sartorelli AC, (1980). Preferential activation of mitomycin C to cytotoxic metabolites by hypoxic tumor cells. Cancer Res 40: 2356-2360.
11. Klymenko T, Brandenburg M, Morrow C, Dive C, Makin G, (2011). The novel Bcl-2 inhibitor ABT-737 is more effective in hypoxia and is able to reverse hypoxia-induced drug resistance in neuroblastoma cells. Mol Cancer Ther 10: 2373-2383.
12. Liu L, Cao Y, Chen C, Zhang X, McNabola A, Wilkie D, et al. (2006). Sorafenib blocks the RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5. Cancer Res 66: 11851-11858.
13. Lombardo LJ, Lee FY, Chen P, Norris D, Barrish JC, Behnia K, et al. (2004). Discovery of N-(2-chloro-6-methyl- phenyl)-2-(6-(4-(2-hydroxyethyl)- piperazin-1-yl)-2-methylpyrimidin-4- ylamino)thiazole-5-carboxamide (BMS-354825), a dual Src/Abl kinase inhibitor with potent antitumor activity in preclinical assays. J Med Chem 47: 6658-6661.
14. Luk CK, Veinot-Drebot L, Tjan E, Tannock IF, (1990). Effect of transient hypoxia on sensitivity to doxorubicin in human and murine cell lines. J Natl Cancer Inst 82: 684-692.
15. McKeage MJ, Gu Y, Wilson WR, Hill A, Amies K, Melink TJ, et al. (2011). A phase I trial of PR-104, a pre-prodrug of the bioreductive prodrug PR-104A, given weekly to solid tumour patients. BMC Cancer 11: 432.
16. Matsuda Y, Fukumoto M, (2011). Sorafenib: complexities of Raf-dependent and Raf-independent signaling are now unveiled. Med Mol Morphol 44: 183-189.
17. Minakata K, Takahashi F, Nara T, Hashimoto M, Tajima K, Murakami A, et al. (2012). Hypoxia induces gefitinib resistance in non-small-cell lung cancer with both mutant and wild-type epidermal growth factor receptors. Cancer Sci 103: 1946-1954.
18. Minchinton AI, Tannock IF, (2006). Drug penetration in solid tumours. Nat Rev Cancer 6: 583-592.
19. Misra A, Pandey C, Sze SK, Thanabalu T, (2012). Hypoxia activated EGFR signaling induces epithelial to mesenchymal transition (EMT). Plos ONE 7: e49766.
20. Montero JC, Seoane S, Ocana A, Pandiella A, (2011). Inhibition of SRC family kinases and receptor tyrosine kinases by dasatinib: possible combinations in solid tumors. Clin Cancer Res 17: 5546-5552.
21. Murakami M, Zhao S, Zhao Y, Chowdhury NF, Yu W, Nishijima K, et al. (2012). Evaluation of changes in the tumor microenvironment after sorafenib therapy by sequential histology and 18F-fluoromisonidazole hypoxia imaging in renal cell carcinoma. Int J Oncol 41: 1593-1600.
22. Onishi H, Morifuji Y, Kai M, Suyama K, Iwasaki H, Katano M, (2012). Hedgehog inhibitor decreases chemosensitivity to 5-fluorouracil and gemcitabine under hypoxic conditions in pancreatic cancer. Cancer Sci 103: 1272-1279.
23. Pham NA, Magalhaes JM, Do T, Schwock J, Dhani N, Cao PJ, et al. (2009). Activation of Src and Src-associated signaling pathways in relation to hypoxia in human cancer xenograft models. Int J Cancer 124: 280-286.
24. Phillips RM, Hulbert PB, Bibby MC, Sleigh NR, Double JA, (1992). In vitro activity of the novel indoloquinone EO-9 and the influence of pH on cytotoxicity. Br J Cancer 65: 359-364.
25. Raju U, Riesterer O, Wang ZQ, Molkentine DP, Molkentine JM, Johnson FM, et al. (2012). Dasatinib, a multi-kinase inhibitor increased radiation sensitivity by interfering with nuclear localization of epidermal growth factor receptor and by blocking DNA repair pathways. Radiother Oncol 105: 241-249.
26. Rohwer N, Cramer T, (2011). Hypoxia-mediated drug resistance: novel insights on the functional interaction of HIFs and cell death pathways. Drug Resist Updat 14: 191-201.
27. Roskoski R, Jr, (2005). Src kinase regulation by phosphorylation and dephosphorylation. Biochem Biophys Res Commun 331: 1-14.
28. Sartorelli AC, Hodnick WF, Belcourt MF, Tomasz M, Haffty B, Fischer JJ, et al. (1994). Mitomycin C: a prototype bioreductive agent. Oncol Res 6: 501-508.
29. Semenza GL, (2012). Molecular mechanisms mediating metastasis of hypoxic breast cancer cells. Trends Mol Med 18: 534-543.
30. Sun JD, Liu Q, Wang J, Ahluwalia D, Ferraro D, Wang Y, et al. (2012). Selective tumor hypoxia targeting by hypoxia-activated prodrug TH-302 inhibits tumor growth in preclinical models of cancer. Clin Cancer Res 18: 758-770.
31. Suwaki N, Vanhecke E, Atkins KM, Graf M, Swabey K, Huang P, et al. (2011). A HIF-regulated VHL-PTP1B-Src signaling axis identifies a therapeutic target in renal cell carcinoma. Sci Transl Med 3: 85ra47.
32. Tang TC, Man S, Xu P, Francia G, Hashimoto K, Emmenegger U, et al. (2010). Development of a resistance-like phenotype to sorafenib by human hepatocellular carcinoma cells is reversible and can be delayed by metronomic UFT chemotherapy. Neoplasia 12: 928-940.
33. Teicher BA, Lazo JS, Sartorelli AC, (1981). Classification of antineoplastic agents by their selective toxicities toward oxygenated and hypoxic tumor cells. Cancer Res 41: 73-81.
34. Tryfonopoulos D, Walsh S, Collins DM, Flanagan L, Quinn C, Corkery B, et al. (2011). Src: a potential target for the treatment of triple-negative breast cancer. Ann Oncol 22: 2234-2240.
35. Vaupel P, (2008). Hypoxia and aggressive tumor phenotype: implications for therapy and prognosis. Oncologist 13 (Suppl 3): 21-26.
36. Vaupel P, (2010). Metabolic microenvironment of tumor cells: a key factor in malignant progression. Exp Oncol 32: 125-127.
37. Vaupel P, Kelleher DK, (2013). Blood flow and oxygenation status of prostate cancers. Adv Exp Med Biol 765: 299-305.
38. Wang X, Schneider A, (2010). HIF-2alpha-mediated activation of the epidermal growth factor receptor potentiates head and neck cancer cell migration in response to hypoxia. Carcinogenesis 31: 1202-1210.
39. Wang X, Zhang L, Goldberg SN, Bhasin M, Brown V, Alsop DC, et al. (2011). High dose intermittent sorafenib shows improved efficacy over conventional continuous dose in renal cell carcinoma. J Transl Med 9: 220-228.
40. Weiss GJ, Infante JR, Chiorean EG, Borad MJ, Bendell JC, Molina JR, et al. (2011). Phase 1 study of the safety, tolerability, and pharmacokinetics of TH-302, a hypoxia-activated prodrug, in patients with advanced solid malignancies. Clin Cancer Res 17: 2997-3004.
41. Wilson WR, Hay MP, (2011). Targeting hypoxia in cancer therapy. Nat Rev Cancer 11: 393-410.
42. Wouters A, Boeckx C, Vermorken JB, Van den Weyngaert D, Peeters M, Lardon F, (2013). The intriguing interplay between therapies targeting the epidermal growth factor receptor, the hypoxic microenvironment and hypoxia-inducible factors. Curr Pharm Des 19: 907-917.
43. Wu YC, Ling TY, Lu SH, Kuo HC, Ho HN, Yeh SD, et al. (2012). Chemotherapeutic sensitivity of testicular germ cell tumors under hypoxic conditions is negatively regulated by SENP1-controlled sumoylation of OCT4. Cancer Res 72: 4963-4973.
44. Yeatman TJ, (2004). A renaissance for SRC. Nat Rev Cancer 4: 470-480.
45. Zhang L, Bhasin M, Schor-Bardach R, Wang X, Collins MP, Panka D, et al. (2011). Resistance of renal cell carcinoma to sorafenib is mediated by potentially reversible gene expression. PLoS ONE 6: e19144.
46. Zhang S, Yu D, (2012). Targeting Src family kinases in anti-cancer therapies: turning promise into triumph. Trends Pharmacol Sci 33: 122-128.